Molecular classification and molecular forecasting of breast cancer: ready for clinical application?
暂无分享,去创建一个
C. Caldas | L. Carey | J. Brenton | A. Ahmed
[1] M. Gent,et al. When is a prognostic factor useful? A guide for the perplexed. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] W. L. McGuire,et al. Breast cancer prognostic factors: evaluation guidelines. , 1991, Journal of the National Cancer Institute.
[3] Mike Clarke,et al. UK and USA breast cancer deaths down 25% in year 2000 at ages 20–69 years , 2000, The Lancet.
[4] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[5] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[6] Douglas G Altman,et al. Systematic reviews of evaluations of prognostic variables , 2001, BMJ : British Medical Journal.
[7] Christine Solbach,et al. Identification of high risk breast-cancer patients by gene expression profiling , 2002, The Lancet.
[8] Yudong D. He,et al. Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.
[9] Carlos Caldas,et al. Cancer: The molecular outlook , 2002, Nature.
[10] Yudong D. He,et al. A Gene-Expression Signature as a Predictor of Survival in Breast Cancer , 2002 .
[11] M. West,et al. Gene expression predictors of breast cancer outcomes , 2003, The Lancet.
[12] Carlos Caldas,et al. Molecular Classification of Breast Carcinomas Using Tissue Microarrays , 2003, Diagnostic molecular pathology : the American journal of surgical pathology, part B.
[13] Fuad G. Gwadry,et al. Comparing cDNA and oligonucleotide array data: concordance of gene expression across platforms for the NCI-60 cancer cells , 2003, Genome Biology.
[14] R Simon,et al. Diagnostic and prognostic prediction using gene expression profiles in high-dimensional microarray data , 2003, British Journal of Cancer.
[15] Philip M. Long,et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[16] C. Cordon-Cardo,et al. A multigenic program mediating breast cancer metastasis to bone. , 2003, Cancer cell.
[17] Annuska M Glas,et al. Gene expression profiles of primary breast tumors maintained in distant metastases , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[18] A. Jazaeri,et al. Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studies. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[19] M. Radmacher,et al. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. , 2003, Journal of the National Cancer Institute.
[20] Klaus Pantel,et al. Molecular signature associated with bone marrow micrometastasis in human breast cancer. , 2003, Cancer research.
[21] R. Tibshirani,et al. Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[22] Syed Mohsin,et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer , 2003, The Lancet.
[23] John D. Storey,et al. Statistical significance for genomewide studies , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[24] A. Gown,et al. Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.
[25] M. Cronin,et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.
[26] Carlos Caldas,et al. Microarray segmentation methods significantly influence data precision. , 2004, Nucleic acids research.
[27] P. Johnston,et al. The role of BRCA1 in the cellular response to chemotherapy. , 2004, Journal of the National Cancer Institute.
[28] M. Fernö,et al. "Good Old" clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers. , 2004, European journal of cancer.
[29] Richard Simon,et al. When is a genomic classifier ready for prime time? , 2004, Nature Clinical Practice Oncology.
[30] Ming Tan,et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. , 2004, Cancer cell.
[31] Wei Wang,et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. , 2004, Cancer cell.
[32] Michael W Kattan,et al. Evaluating a New Marker’s Predictive Contribution , 2004, Clinical Cancer Research.
[33] A. Ashworth,et al. Hallmarks of 'BRCAness' in sporadic cancers , 2004, Nature Reviews Cancer.
[34] R. Tibshirani,et al. Semi-Supervised Methods to Predict Patient Survival from Gene Expression Data , 2004, PLoS biology.
[35] C. Perou,et al. Race and the poor prognosis basal breast tumor (BBT) phenotype in the population-based Carolina Breast Cancer Study (CBCS). , 2004, Journal of Clinical Oncology.
[36] J. Stec,et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] I. Ellis,et al. Expression of luminal and basal cytokeratins in human breast carcinoma , 2004, The Journal of pathology.
[38] Graham A Colditz,et al. Risk factors for breast cancer according to estrogen and progesterone receptor status. , 2004, Journal of the National Cancer Institute.
[39] Shinzaburo Noguchi,et al. Prediction of docetaxel response in human breast cancer by gene expression profiling. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] Stefan Michiels,et al. Prediction of cancer outcome with microarrays: a multiple random validation strategy , 2005, The Lancet.
[41] Zhao Chen,et al. Ethnicity and breast cancer: factors influencing differences in incidence and outcome. , 2005, Journal of the National Cancer Institute.
[42] Howard Y. Chang,et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[43] Syed Mohsin,et al. Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] Karen A Gelmon,et al. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] W. Gerald,et al. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. , 2005, The Journal of clinical investigation.
[46] Y Wang,et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.
[47] K. Rosenblatt,et al. Phenotypic and proteomic alterations of acquired trastuzumab resistance , 2005 .
[48] E. Winer,et al. HER2 or not HER2: that is the question. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] Eytan Domany,et al. Outcome signature genes in breast cancer: is there a unique set? , 2004, Breast Cancer Research.
[50] J. Foekens,et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.
[51] H. Rugo,et al. Phase II study of SU11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC) , 2005 .
[52] Manuela Gariboldi,et al. Limits of predictive models using microarray data for breast cancer clinical treatment outcome. , 2005, Journal of the National Cancer Institute.
[53] Daniel J Sargent,et al. Clinical trial designs for predictive marker validation in cancer treatment trials. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] M. Cronin,et al. Expression of the 21 genes in the Recurrence Score assay and tamoxifen clinical benefit in the NSABP study B-14 of node negative, estrogen receptor positive breast cancer , 2005 .
[55] 佐治 重衡,et al. What's going on 乳癌 A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Ma XJ, Wang Z, Ryan PD, Isakoff SJ, Barmettler A, Fuller A, et al. Cancer Cell. 2004;5:607-16. PMID:15193263--術後補助療法におけるタモキシフェンへの反応性は2つの遺伝子レベルの測定によって予測しうることを示した論文 , 2005 .
[56] Roman Rouzier,et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] G. Ball,et al. High‐throughput protein expression analysis using tissue microarray technology of a large well‐characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses , 2005, International journal of cancer.
[58] R. Simon,et al. Development and validation of therapeutically relevant multi-gene biomarker classifiers. , 2005, Journal of the National Cancer Institute.
[59] Daniel Birnbaum,et al. Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. , 2005, Cancer research.